Development and application of hyaluronic acid in tumor targeting drug delivery

Luo, Zhigang; Dai, Yan; Gao, Huile

doi:10.1016/j.apsb.2019.06.004

Cited by 263 publications

(132 citation statements)

References 109 publications

Supporting

Mentioning

130

Contrasting

Order By: Relevance

“…Nanoscale HA systems appear to be very effective tumor targeting vehicles particularly if they are tailored with controlled drug release means. They can be as effective as and with even more in vivo success compared to other nanoparticle tumor targeting vehicles [111,112]. Liu et al [113] fabricated cationic small-sized red emission BSA-protected gold nanocluster (AuNC@CBSA, 21.06 nm) in order to encapsulate indocyanine green (ICG) as imaging agent and also to realize theranostic treatment.…”

Section: Hyaluronic Acid and Cancer Targeting Drugsmentioning

confidence: 99%

Hyaluronic Acid and Controlled Release: A Review

2020

View full text Add to dashboard Cite

Hyaluronic acid (HA) also known as hyaluronan, is a natural polysaccharide—an anionic, non-sulfated glycosaminoglycan—commonly found in our bodies. It occurs in the highest concentrations in the eyes and joints. Today HA is used during certain eye surgeries and in the treatment of dry eye disease. It is a remarkable natural lubricant that can be injected into the knee for patients with knee osteoarthritis. HA has also excellent gelling properties due to its capability to bind water very quickly. As such, it is one the most attractive controlled drug release matrices and as such, it is frequently used in various biomedical applications. Due to its reactivity, HA can be cross-linked or conjugated with assorted bio-macromolecules and it can effectively encapsulate several different types of drugs, even at nanoscale. Moreover, the physiological significance of the interactions between HA and its main membrane receptor, CD44 (a cell-surface glycoprotein that modulates cell–cell interactions, cell adhesion and migration), in pathological processes, e.g., cancer, is well recognized and this has resulted in an extensive amount of studies on cancer drug delivery and tumor targeting. HA acts as a therapeutic but also as a tunable matrix for drug release. Thus, this review focuses on controlled or sustained drug release systems assembled from HA and its derivatives. More specifically, recent advances in controlled release of proteins, antiseptics, antibiotics and cancer targeting drugs from HA and its derivatives were reviewed. It was shown that controlled release from HA has many benefits such as optimum drug concentration maintenance, enhanced therapeutic effects, improved efficiency of treatment with less drug, very low or insignificant toxicity and prolonged in vivo release rates.

show abstract

Section: Hyaluronic Acid and Cancer Targeting Drugsmentioning

confidence: 99%

Hyaluronic Acid and Controlled Release: A Review

2020

View full text Add to dashboard Cite

show abstract

“…Like other types of NP, nanogels can be provided not only passive targeting ability by adjustments to their size, shape or surface property, but also active targeting by their surface modification, further improving the accumulation of drugs in disease region [58]. Active targeting can be achieved through the interaction of ligands and specific cellular or subcellular receptors.…”

Section: Modification Of Nanogels For Active Targetingmentioning

confidence: 99%

Nanogel: A Versatile Nano-Delivery System for Biomedical Applications

et al. 2020

Self Cite

View full text Add to dashboard Cite

Nanogel-based nanoplatforms have become a tremendously promising system of drug delivery. Nanogels constructed by chemical crosslinking or physical self-assembly exhibit the ability to encapsulate hydrophilic or hydrophobic therapeutics, including but not limited to small-molecule compounds and proteins, DNA/RNA sequences, and even ultrasmall nanoparticles, within their 3D polymer network. The nanosized nature of the carriers endows them with a specific surface area and inner space, increasing the stability of loaded drugs and prolonging their circulation time. Reactions or the cleavage of chemical bonds in the structure of drug-loaded nanogels have been shown to trigger the controlled or sustained drug release. Through the design of specific chemical structures and different methods of production, nanogels can realize diverse responsiveness (temperature-sensitive, pH-sensitive and redox-sensitive), and enable the stimuli-responsive release of drugs in the microenvironments of various diseases. To improve therapeutic outcomes and increase the precision of therapy, nanogels can be modified by specific ligands to achieve active targeting and enhance the drug accumulation in disease sites. Moreover, the biomembrane-camouflaged nanogels exhibit additional intelligent targeted delivery features. Consequently, the targeted delivery of therapeutic agents, as well as the combinational therapy strategy, result in the improved efficacy of disease treatments, though the introduction of a multifunctional nanogel-based drug delivery system.

show abstract

“…The clinical efficacy and outcome of conventional molecular chemotherapeutics against tumors are limited by several undesirable properties, including the poor solubility, the short half-life in vivo , the weak penetration capability, and the low specificity (Tang et al, 2014 ; Liu et al, 2016 ; Wang et al, 2017 , 2018 ; Luo et al, 2019 ). To overcome these drawbacks of conventional cancer chemotherapeutics, various nanoparticle-based drug delivery systems (DDSs) have been developed (Versluis et al, 2016 ; Gerbelli et al, 2019 ; Xiao et al, 2019b ).…”

Section: Introductionmentioning

confidence: 99%

Tumor Microenvironment–Responsive Peptide-Based Supramolecular Drug Delivery System

Zhang

et al. 2020

Front. Chem.

View full text Add to dashboard Cite

Physical and biochemical differences between tumor tissues and normal tissues provide promising triggering factors that can be utilized to engineer stimuli-responsive drug delivery platforms for cancer treatment. Rationally designed peptide-based supramolecular architectures can perform structural conversion by responding to the tumor microenvironment and achieve the controlled release of antitumor drugs. This mini review summarizes recent approaches for designing internal trigger-responsive drug delivery platforms using peptide-based materials. Peptide assemblies that exhibit a stimuli-responsive structural conversion upon acidic pH, high temperature, high oxidative potential, and the overexpressed proteins in tumor tissues are emphatically introduced. We also discuss the challenges of current peptide-based supramolecular delivery platforms against cancer.

show abstract

Development and application of hyaluronic acid in tumor targeting drug delivery

Cited by 263 publications

References 109 publications

Hyaluronic Acid and Controlled Release: A Review

Hyaluronic Acid and Controlled Release: A Review

Nanogel: A Versatile Nano-Delivery System for Biomedical Applications

Tumor Microenvironment–Responsive Peptide-Based Supramolecular Drug Delivery System

Contact Info

Product

Resources

About